ArticleJournal of clinical medicine2023
Benralizumab Effectiveness in Severe Eosinophilic Asthma with Co-Presence of Bronchiectasis: A Real-World Multicentre Observational Study.
Article in Journal of clinical medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 27 citations in OpenAlex.
- Targeting Inflammation in Bronchiectasis.Drugs · 2026Review
- Therapies for bronchiectasis: mechanisms and potential effects.Frontiers in immunology · 2026Review
- Achieving remission in severe asthma.Chinese medical journal pulmonary and critical care medicine · 2025Review
- Long-Term Clinical Remission on Benralizumab Treatment in Severe Eosinophilic Asthma: A Four-Year Real-Life Study.Journal of clinical medicine · 2025Article
- Clinical Remission Predictors in Non-Colonized Bronchiectasis and Severe Asthma with Type 2-Targeted Biologic Therapy: A Retrospective Real-Life Pilot Study.Journal of clinical medicine · 2024Article
- Eosinophilic Bronchiectasis: Prevalence, Severity, and Associated Features-A Cohort Study.Journal of clinical medicine · 2024Article
- Unlocking the Long-Term Effectiveness of Benralizumab in Severe Eosinophilic Asthma: A Three-Year Real-Life Study.Journal of clinical medicine · 2024Article
- The Role of Galectins in Asthma Pathophysiology: A Comprehensive Review.Current issues in molecular biology · 2024Review
- Features of severe asthma response to anti-IL5/IL5r therapies: identikit of clinical remission.Frontiers in immunology · 2024Article
- Personalized Medicine in Asthma: Current Approach and Future Perspectives.Journal of personalized medicine · 2023Article
- Management of comorbidities in difficult and severe asthma.Breathe (Sheffield, England) · 2023Review
- Association of blood total immunoglobulin E and eosinophils with radiological features of bronchiectasis.BMC pulmonary medicine · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 8 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.